From Zacks Investment Research: 2025-05-23 17:08:00

Roche (RHHBY) received FDA approval for Susvimo to treat diabetic retinopathy, marking its third approved indication. The drug offers vision maintenance with just one treatment every nine months. The approval was based on positive results from the Pavilion study, showing superior improvements in patients receiving Susvimo. Roche’s ophthalmology portfolio also includes Vabysmo, the first bispecific antibody for eye treatment. Regeneron faces competition from Roche’s drugs, impacting Eylea sales. Roche stock has risen 14.4% YTD. Other top-ranked pharma stocks include Novartis and Pfizer, both with a Zacks Rank #2. Novartis and Pfizer have seen an increase in EPS estimates for 2025 and 2026.



Read more at Zacks Investment Research: Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication – May 23, 2025